Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
Date:9/22/2010

R 20 response criteria is defined as greater than or equal to 20% improvement from baseline in both tender and swollen joints, and greater than or equal to 20% improvement in three of five measures: pain, acute phase reactant, physical function, patient and physician global assessment. ACR 50 and ACR 70 assess greater than or equal to 50% improvement and greater than or equal to 70% improvement in those areas respectively. ** DAS 28 is a measure of the activity of Rheumatoid Arthritis assessing 28 joint counts in the body

About Fostamatinib

Fostamatinib (previously referred to as R788), is the first oral syk inhibitor in development as a novel therapeutic approach for RA. It is thought to reversibly block signalling in multiple cell types involved in inflammation and tissue degradation in RA.

In February 2010, AstraZeneca and Rigel Pharmaceuticals announced a worldwide license agreement whereby AstraZeneca will develop and commercialise fostamatinib.

About RA

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, which causes damage to the joints and other organs, affecting approximately 1 in 100 people. It is a major cause of disability and is also associated with reduced life expectancy, especially if not adequately treated.

About the TASKi2 Study Design

TASKi2 was a 6 month, multi-center, randomized, double-blind, placebo controlled, parallel dose clinical trial involving 457 RA patients in the U.S., Latin America and Europe who had active RA despite treatment with MTX alone. Approximately 1/3 of the patients (n=152) studied received 100mg of fostamatinib orally bid. Another third received 150mg of the study drug qd and the final third were given placebo to be taken orally bid or qd (total placebo n=153). Throughout the study all patients continued to receive their stable dose of MTX.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business wit
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... 2009 First Quarter Highlights , , , ... million in the first quarter of 2008 , ... first quarter of 2008 , Saflex ... The Company,s cash generation in the quarter allowed for debt ...
... 6 ChanTest, the leading expert in ion channels ... discovery, development, and safety -- is one of eight ... Research and Commercialization Program. Governor Ted Strickland and Interim ... of the Ohio Third Frontier Commission, Mark Barbash, announced ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
Cached Biology Technology:Solutia Reports First Quarter 2009 Results 2Solutia Reports First Quarter 2009 Results 3Solutia Reports First Quarter 2009 Results 4Solutia Reports First Quarter 2009 Results 5Solutia Reports First Quarter 2009 Results 6Solutia Reports First Quarter 2009 Results 7Solutia Reports First Quarter 2009 Results 8Solutia Reports First Quarter 2009 Results 9Solutia Reports First Quarter 2009 Results 10Solutia Reports First Quarter 2009 Results 11Solutia Reports First Quarter 2009 Results 12Solutia Reports First Quarter 2009 Results 13Solutia Reports First Quarter 2009 Results 14Solutia Reports First Quarter 2009 Results 15Solutia Reports First Quarter 2009 Results 16Solutia Reports First Quarter 2009 Results 17Solutia Reports First Quarter 2009 Results 18Solutia Reports First Quarter 2009 Results 19Solutia Reports First Quarter 2009 Results 20Solutia Reports First Quarter 2009 Results 21ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... Clemson professor Rajendra Singh Thursday as a "Champion ... expand solar deployment in the residential, commercial and ... Professor of Electrical and Computer Engineering and director ... a local hero leading the charge across the ... solar power and driving policy changes at the ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... Center have discovered a basic mechanism by which smooth ... ?sometimes abnormally ?suggesting methods of treatment for various coronary ... involved in hypertension, coronary artery disease, tumors called leiosarcomas ... it is now possible to begin to design therapies ...
... different rates, and the evolutionary line that produced humans seems ... new study by scientists at the European Molecular Biology Laboratory ... very ancient ancestor that have been lost in more quickly-evolving ... genes in the first animals. The work appears in the ...
... warblers and beaver dams once were bountiful in an area ... left this area, elk grew more plentiful, browsing heavily on ... sparrows have replaced the warblers in what is now a ... of the wolf, a top predator. That's the compelling finding ...
Cached Biology News:UT Southwestern researchers unravel control of growing blood vessels 2The earliest animals had human-like genes 2The earliest animals had human-like genes 3Wolves' top-down effect 2